Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Kyle Blankenship

Bristol Myers Squibb shook the CAR-T field earlier this month with a breakthrough win in earlier-line blood cancer patients with the promise of changing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Kyle Blankenship

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Gilead­'s Kite earns sec­ond-line win for CAR-T Yescar­ta, set­ting up a bat­tle over ear­li­er blood can­cer pa­tients

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients